| 1. Patients with characteristics similar with those enrolled in the APT trial, such as cT1N0 disease, may be considered for upfront surgery followed by standard adjuvant treatment. | II | B | 1,2 |
| 2. In the adjuvant setting for HER2-positive early breast cancer (EBC), a trastuzumab-based regimen is recommended, with the addition of pertuzumab (IV or SC) for patients with lymph node–positive disease. | I | A | 2,3,4 |
| 3.In the neoadjuvant setting for HER2-positive EBC, trastuzumab-based regimen with or without pertuzumab (IV or SC) is recommended. | 1 | A | 2,5,6 |
| 4.For patients with HER2-positive EBC, T-DXd followed by THP (IV or SC) is one of the preoperative treatment for those with ≥cT3, N0–3 disease or cT0–4, N1–3 disease. | 1 | A | 7 |
